PubAg

Main content area

Protective effects of astragalus polysaccharide nanoparticles on septic cardiac dysfunction through inhibition of TLR4/NF-κB signaling pathway

Author:
Xu, Xiaoying, Rui, Shaozhen, Chen, Chong, Zhang, Guochao, Li, Zhi, Wang, Jianghua, Luo, Yanping, Zhu, Haiping, Ma, Xingming
Source:
International journal of biological macromolecules 2020 v.153 pp. 977-985
ISSN:
0141-8130
Subject:
Astragalus, C-reactive protein, Toll-like receptor 4, blood serum, cell structures, cell viability, cytokines, drugs, histopathology, inflammation, leukocytes, mice, microbial load, morbidity, mortality, nanoparticles, polysaccharides, protective effect, signal transduction, transcription factor NF-kappa B, troponin I
Abstract:
Sepsis-induced myocardial dysfunction was the leading cause of morbidity and mortality in hospitalized patients and yet there were no effective therapies. With excessive released inflammatory mediators through the TLR4-trigger NF-κB signaling pathway being implicated as key players in sepsis-induced myocardial injury, we prepared astragalus polysaccharide (APS) nanoparticles as an TLR4-responsive drug for alleviating sepsis-induced myocardial injury. Firstly, treatment with APS nanoparticles in LPS-treated H9c2 cells to evaluate the direct effect demonstrated that this drug maintained the cell viability, cell morphology and exerted anti-apoptotic effects. Additionally, animal studies using cecal ligation and puncture (CLP) in C57BL/6 mice revealed that APS nanoparticles were much more efficacious in attenuating sepsis-induced myocardial injury by down-regulating the bacterial loads, inhibiting serum C-reactive protein (CRP), white blood cells (WBC) levels, alleviating myocardial histopathologic abnormalities, remarkably reducing the cardiac troponin I (cTnI). Moreover, APS nanoparticles significantly decreased the myocardial inflammatory cytokine expression and inhibited the activity of TLR4/NF-κB pathway. In conclusion, APS nanoparticles could protect the sepsis-induced cardiac dysfunction. The mechanism of the protective action of APS nanoparticles seems to involve its ability to reduce inflammatory response and to suppress TLR4/NF-κB pathway. This drug may be a potential candidate strategy for septic cardiac dysfunction treatment.
Agid:
6774912